Soleno Therapeutics (SLNO) News Today $57.09 -0.02 (-0.04%) (As of 04:26 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cantor Fitzgerald Remains a Buy on Soleno Therapeutics (SLNO)November 8 at 1:32 PM | markets.businessinsider.comSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 6 at 5:52 PM | finance.yahoo.comHarbor Capital Advisors Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Harbor Capital Advisors Inc. purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 36,048 shares of the company's stock, valued at approximately $1,82November 6 at 4:40 AM | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Stock, Option ChainNovember 3, 2024 | benzinga.comEmerald Advisers LLC Increases Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Emerald Advisers LLC raised its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 6.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 313,334 shares of the company's stock after buying an additioNovember 3, 2024 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by AnalystsNovember 1, 2024 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Recommendation of "Buy" by AnalystsShares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy raNovember 1, 2024 | marketbeat.comOppenheimer Increases Soleno Therapeutics (NASDAQ:SLNO) Price Target to $73.00October 30, 2024 | americanbankingnews.comSoleno Therapeutics price target raised to $73 from $65 at OppenheimerOctober 29, 2024 | markets.businessinsider.comSoleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month High on Analyst UpgradeSoleno Therapeutics (NASDAQ:SLNO) Hits New 1-Year High on Analyst UpgradeOctober 28, 2024 | marketbeat.comSoleno Therapeutics to Participate in Upcoming November Investor ConferencesOctober 28, 2024 | tmcnet.comSoleno Therapeutics announces passing of former chairman Ernest MarioOctober 22, 2024 | markets.businessinsider.comSoleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.October 21, 2024 | markets.businessinsider.comSoleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCROctober 16, 2024 | msn.comSoleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome TreatmentOctober 16, 2024 | insidermonkey.com10 Biggest Stocks with Negative Beta to ConsiderOctober 14, 2024 | insidermonkey.comSoleno Therapeutics (NASDAQ:SLNO) Trading 6.4% Higher - Still a Buy?Soleno Therapeutics (NASDAQ:SLNO) Trading 6.4% Higher - Time to Buy?October 11, 2024 | marketbeat.comCarlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc.October 10, 2024 | finance.yahoo.comSoleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia TreatmentsOctober 10, 2024 | seekingalpha.comThe Manufacturers Life Insurance Company Raises Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)The Manufacturers Life Insurance Company lifted its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 120.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,408 shares of the company's stOctober 10, 2024 | marketbeat.comBelite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On OculisOctober 9, 2024 | markets.businessinsider.comSoleno Therapeutics Jumps After FDA Says No Advisory Panel Meeting Needed for Prader-Willi Syndrome DrugOctober 8, 2024 | marketwatch.comSoleno Therapeutics Says FDA Determines No Need For Advisory Committee Meeting For DCCR NDAOctober 8, 2024 | markets.businessinsider.comSoleno stock rises as NDA for lead asset doesn’t need FDA advisory meetingOctober 8, 2024 | msn.comSoleno Therapeutics's Options Frenzy: What You Need to KnowOctober 8, 2024 | benzinga.comSoleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi SyndromeOctober 8, 2024 | markets.businessinsider.comSLNO Stock Rises as Prader-Willi Treatment Nears FDA ApprovalOctober 8, 2024 | gurufocus.comWhy Soleno Therapeutics Stock Blasted 9% Higher TodayOctober 8, 2024 | fool.comSoleno Therapeutics Target of Unusually Large Options Trading (NASDAQ:SLNO)Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Stock traders bought 11,478 put options on the stock. This represents an increase of approximately 1,203% compared to the average daily volume of 881 put options.October 8, 2024 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year High - Still a Buy?Soleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month High - Here's WhyOctober 8, 2024 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of "Buy" by AnalystsShares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been given an average rating of "Buy" by the eight brokerages that are covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating toOctober 7, 2024 | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 3,108 Shares of StockOctober 4, 2024 | insidertrades.comKristen Yen Sells 3,108 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Kristen Yen sold 3,108 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total value of $153,628.44. Following the completion of the transaction, the insider now directly owns 81,465 shares in the company, valued at approximately $4,026,814.95. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.October 3, 2024 | marketbeat.comJanus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics IncOctober 3, 2024 | gurufocus.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Position Raised by Nantahala Capital Management LLCNantahala Capital Management LLC raised its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 27.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,082,107 shares of the company's stock after purchasing an adOctober 1, 2024 | marketbeat.comPerceptive Advisors LLC Raises Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Perceptive Advisors LLC boosted its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,204,976 shares of the company's stock after acquirSeptember 30, 2024 | marketbeat.comNantahala Capital Management Reduces Stake in America's Car-Mart IncSeptember 24, 2024 | finance.yahoo.comSamlyn Capital LLC Purchases 282,122 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)Samlyn Capital LLC lifted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 128.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 501,049 shares of the company's stock aSeptember 24, 2024 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Holdings Lifted by Avoro Capital Advisors LLCAvoro Capital Advisors LLC grew its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 28.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,091,666 shares of the companySeptember 23, 2024 | marketbeat.comRhumbline Advisers Makes New Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Rhumbline Advisers purchased a new position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 29,144 shares of the company's stock, valued at approximately $1,189,000. RhumblSeptember 22, 2024 | marketbeat.comSoleno Therapeutics' (SLNO) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price target on shares of Soleno Therapeutics in a report on Friday.September 20, 2024 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Reaches New 52-Week High at $54.32Soleno Therapeutics (NASDAQ:SLNO) Reaches New 12-Month High at $54.32September 17, 2024 | marketbeat.comSofinnova Investments Inc. Raises Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Sofinnova Investments Inc. increased its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 267.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 554,359 shares of the company's stock afteSeptember 17, 2024 | marketbeat.comSoleno Therapeutics to Present at 2024 Cantor Global Healthcare ConferenceSeptember 16, 2024 | globenewswire.comBank of New York Mellon Corp Acquires Shares of 88,799 Soleno Therapeutics, Inc. (NASDAQ:SLNO)Bank of New York Mellon Corp bought a new position in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 88,799 shares of the company's stock, valued at approximately $3,623,000. Bank of New YorSeptember 15, 2024 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading VolumeSoleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading VolumeSeptember 13, 2024 | marketbeat.comTD Asset Management Inc Boosts Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)TD Asset Management Inc boosted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 174.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,534 shares of the company's stock aSeptember 13, 2024 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of "Buy" by BrokeragesShares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been given an average recommendation of "Buy" by the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has givenSeptember 12, 2024 | marketbeat.comSoleno Therapeutics (SLNO) Receives a Buy from Piper SandlerSeptember 11, 2024 | markets.businessinsider.comSoleno Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.56) Per Share, HC Wainwright Forecasts (NASDAQ:SLNO)Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Investment analysts at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for shares of Soleno Therapeutics in a note issued to investors on Tuesday, September 3rd. HC Wainwright analyst R. Selvaraju expects that the compaSeptember 6, 2024 | marketbeat.com Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 stocks that can double in 2024 (Ad)You still have time to access the 5 Stocks that Can Double in 2024 report for free. Download your free report today! SLNO Media Mentions By Week SLNO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLNO News Sentiment▼0.290.36▲Average Medical News Sentiment SLNO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLNO Articles This Week▼63▲SLNO Articles Average Week Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rhythm Pharmaceuticals News Rockwell Medical News Edap Tms News FONAR News BioSig Technologies News Bausch + Lomb News Glaukos News Inspire Medical Systems News PROCEPT BioRobotics News TransMedics Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLNO) was last updated on 11/8/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThis is treasonIf you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | SponsoredWhat Trump’s victory means for GOLDGold may have suffered a pullback after news of Trump's 2024 election win spread... But don't be mistaken: ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
